Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBM-A101 in Knee Osteoarthritis
NCT07198555Phase 1Recruiting
- Sponsor
- Belief BioMed Inc.
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in knee osteoarthritis (OA) comparing Arm of BBM-A101 with Arm of Placebo (2 arms). Primary endpoints: Incidence of dose limiting toxicity events at 4 weeks and Incidence of Adverse Events and Serious Adverse Events at 52 weeks. Started Oct 2025; status: recruiting.
02
Drugs
BBM-A101
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07198555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198555.